Avenue Therapeutics Files 8-K Report
Ticker: ATXI · Form: 8-K · Filed: May 23, 2024 · CIK: 1644963
| Field | Detail |
|---|---|
| Company | Avenue Therapeutics, INC. (ATXI) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K, something happened, more details to come.
AI Summary
On May 21, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself, but it was submitted on May 23, 2024, and pertains to the company's operations.
Why It Matters
This filing indicates a material event has occurred for Avenue Therapeutics, Inc., requiring public disclosure. Investors should monitor for further information to understand the event's impact.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for an 'Other Event' without immediate disclosed financial or operational impact, making the immediate risk low.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
- May 23, 2024 (date) — Filing date
FAQ
What specific event is reported in the 8-K filing?
The filing is categorized under 'Other Events' and does not specify the exact nature of the event.
When was the earliest event reported?
The earliest event reported was on May 21, 2024.
When was the 8-K form filed with the SEC?
The 8-K form was filed on May 23, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.
What is Avenue Therapeutics, Inc.'s telephone number?
Avenue Therapeutics, Inc.'s telephone number is (781) 652-4500.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2024-05-23 08:30:20
Filing Documents
- atxi20240522_8k.htm (8-K) — 22KB
- 0001437749-24-018072.txt ( ) — 151KB
- atxi-20240521.xsd (EX-101.SCH) — 3KB
- atxi-20240521_def.xml (EX-101.DEF) — 11KB
- atxi-20240521_lab.xml (EX-101.LAB) — 15KB
- atxi-20240521_pre.xml (EX-101.PRE) — 11KB
- atxi20240522_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On May 21, 2024, Avenue Therapeutics, Inc. (the " Company ") received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market (the " Nasdaq "), including the minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the " Equity Rule "). As a result, the previously disclosed listing matter has been closed. Notwithstanding the closing of the matter, the Company was also notified that it will remain subject to a "Panel Monitor," as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year, through May 21, 2025. If, during the term of the Panel Monitor, the Company does not satisfy the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for the Listing Qualifications Staff's review. The Company will instead be required to request a hearing before the Nasdaq Hearings Panel to address the deficiency, with such request staying any further action with respect to the Company's listing on Nasdaq pending completion of the hearing process.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: May 23, 2024 By: /s/ David Jin David Jin Interim Principal Financial Officer and Chief Operating Officer